Johnson & Johnson's earnings call highlighted strong operational performance, exceeding expectations in several areas, particularly in the Pharmaceutical segment.  Management emphasized continued investment in innovation and a focus on strategic acquisitions and partnerships. The call also detailed plans for cost reductions ($1 billion by 2018), providing investors with a picture of a profitable business looking to sustain strong growth.  These factors suggest a positive short-term impact on the stock price. 
[1]
